Cargando…

Sensitive detection of low-abundance in-frame deletions in EGFR exon 19 using novel wild-type blockers in real-time PCR

Epidermal growth factor receptor (EGFR) mutations are associated with response of tyrosine kinase inhibitors (TKIs) for patients with advanced non-small cell lung cancer (NSCLC). However, the existing methods for detection of samples having rare mutations(i.e. ~0.01%) have limits in terms of specifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Xiao-Dong, Liu, Ding-Yuan, Guo, Hai-Qin, Wang, Liu, Zhao, Na, Su, Ning, Wei, Kun, Ren, Sai, Qu, Xue-Mei, Dai, Xiao-Tian, Huang, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547704/ https://www.ncbi.nlm.nih.gov/pubmed/31164704 http://dx.doi.org/10.1038/s41598-019-44792-1

Ejemplares similares

Fluorometric Detection of Low-Abundance EGFR Exon 19 Deletion Mutation Using Tandem Gene Amplification
por: Kim, Dong-Min, et al.
Publicado: (2020)

In-Frame Deletion of Dystrophin Exons 8–50 Results in DMD Phenotype
por: Egorova, Tatiana V., et al.
Publicado: (2023)

Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies
por: Toh, Zhi Yon Charles, et al.
Publicado: (2016)

A Genotype-Phenotype Correlation Study of Exon Skip-Equivalent In-Frame Deletions and Exon Skip-Amenable Out-of-Frame Deletions across the DMD Gene to Simulate the Effects of Exon-Skipping Therapies: A Meta-Analysis
por: Anwar, Saeed, et al.
Publicado: (2021)

MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion
por: Ju, Lixia, et al.
Publicado: (2017)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations
por: Vliegen, Liesbet, et al.
Publicado: (2015)

3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma
por: Liu, Guixue, et al.
Publicado: (2020)

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma
por: Dahse, R, et al.
Publicado: (2008)

Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
por: Tamirat, Mahlet Z., et al.
Publicado: (2019)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
por: Peng, MuYun, et al.
Publicado: (2020)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

Detection of internal exon deletion with exon Del
por: Guo, Yan, et al.
Publicado: (2014)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion
por: Weiss, Glen J., et al.
Publicado: (2013)

The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms
por: Wang, Taishu, et al.
Publicado: (2018)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis
por: Pan, Xin-Bin, et al.
Publicado: (2022)

Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer
por: Jin, Ying, et al.
Publicado: (2016)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Abundant Microsatellite Diversity and Oil Content in Wild Arachis Species
por: Huang, Li, et al.
Publicado: (2012)

Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs
por: Xu, Chun-wei, et al.
Publicado: (2020)

Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer
por: Brown, Benjamin P., et al.
Publicado: (2022)

Predicting mutually exclusive spliced exons based on exon length, splice site and reading frame conservation, and exon sequence homology
por: Pillmann, Holger, et al.
Publicado: (2011)

Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report
por: Jing, Wei, et al.
Publicado: (2020)

CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations
por: Ramteke, Manoj P., et al.
Publicado: (2016)

Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
por: Costa, D B, et al.
Publicado: (2007)

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
por: Marchetti, Antonio, et al.
Publicado: (2012)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
por: Tokudome, Nahomi, et al.
Publicado: (2020)

Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion
por: Zu, Yunfen, et al.
Publicado: (2021)

CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
por: Mou, Haiwei, et al.
Publicado: (2017)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Wang, Yurong, et al.
Publicado: (2021)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
por: Chen, Shubin, et al.
Publicado: (2023)

Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
por: O’Sullivan, Dylan E., et al.
Publicado: (2022)

Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms
por: Pettigrew, Christopher, et al.
Publicado: (2005)

Abundance of clinical variants in exons included in multiple transcripts
por: Subramanian, Sankar
Publicado: (2018)

Scorpion primer PCR analysis for genotyping of allele variants of thiopurine s-methyltransferase*3
por: Yao, Pu, et al.
Publicado: (2020)

A birth of bipartite exon by intragenic deletion
por: Nozu, Kandai, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0vlg440rabojgsgkjmd2ldjsjj